Janux Therapeutics, Inc. (JANX) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	31.9M	10.0M	10.6M	8.1M	8.6M
Cost of Revenue	9.9M	2.0M	2.1M	2.0M	841.0K
Gross Profit	22.0M	8.0M	8.5M	6.1M	7.8M
Operating Expenses
R&D Expense	124.0M	125.9M	68.4M	54.9M	53.4M
SG&A Expense	43.1M	41.8M	41.0M	26.1M	22.3M
General & Admin Expense	32.9M	41.8M	41.0M	26.1M	22.3M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(1.5M)	(2.0M)	(2.1M)	(2.0M)	(841.0K)
Total Operating Expenses	165.5M	165.6M	107.4M	79.1M	74.9M
Cost and Expenses	175.4M	167.7M	109.4M	81.1M	75.7M
Operating Income (EBIT)	(143.6M)	(157.7M)	(98.8M)	(73.0M)	(67.1M)
Non-Operating
Interest Income	64.5M	44.0M	29.9M	14.7M	4.0M
Interest Expense	—	—	—	—	—
Net Interest Income	64.5M	44.0M	29.9M	14.7M	4.0M
Other Non-Op Income/Expense	41.0M	44.0M	29.9M	14.7M	4.0M
Non-Operating Income (excl Interest)	(41.0M)	(44.0M)	(29.9M)	(14.7M)	(4.0M)
EBT (Pre-Tax Income)	(102.6M)	(113.6M)	(69.0M)	(58.3M)	(63.1M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(102.6M)	(113.6M)	(69.0M)	(58.3M)	(63.1M)
Earnings from Cont. Ops	(102.6M)	(113.6M)	(69.0M)	(58.3M)	(63.1M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(102.6M)	(113.6M)	(69.0M)	(58.3M)	(63.1M)
Per Share
Basic EPS	($1.64)	($1.83)	($1.28)	($1.32)	($1.52)
Diluted EPS	($1.64)	($1.83)	($1.28)	($1.32)	($1.52)
Revenue Per Share	$0.51	$0.16	$0.20	$0.18	$0.21
Shares
Basic Shares Outstanding	62.9M	62.0M	53.8M	44.0M	41.5M
Diluted Shares Outstanding	62.9M	62.0M	53.8M	44.0M	41.5M
Profitability Metrics
EBITDA	(101.1M)	(111.6M)	(66.9M)	(56.3M)	(62.2M)
D&A	1.5M	2.0M	2.1M	2.0M	841.0K
EBIT	(102.6M)	(113.6M)	(69.0M)	(58.3M)	(63.1M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026